Navigation Links
Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
Date:7/17/2014

THOUSAND OAKS, Calif., July 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. Amgen obtained AMG 416 as part of the acquisition of KAI Pharmaceuticals, Inc. in July 2012 and these are the first results to be reported from the Phase 3 program.

In the AMG 416 group, 75.3 percent of patients achieved a > 30 percent reduction from baseline in PTH compared with 9.6 percent in the placebo arm, a statistically significant result. Secondary endpoints included the percent change from baseline during the EAP in serum phosphorus (P) concentration (mean changes of -9.63 and -1.60 percent among patients in the AMG 416 and placebo arms, respectively) and corrected calcium (cCa) concentration (mean changes of -6.69 and 0.58 percent among patients in the AMG 416 and placebo arms, respectively). Both of these secondary endpoint results were statistically significant.   

"Secondary hyperparathyroidism can be a challenging disease to manage and control. There is an important role for an effective calcimimetic that can be administered intravenously with hemodialysis to help treat this disease," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We are encouraged by the results of this study and look forward to sharing results from a second placebo-controlled study later this year, and a head-to-head study
'/>"/>

SOURCE Amgen
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease
2. Amgen To Present At The 32nd Annual J.P. Morgan Healthcare Conference
3. Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer
4. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
5. Amgen Announces 2014 First Quarter Dividend
6. Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
7. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
8. Amgens Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
9. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
10. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
11. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... Hologic,s President and Chief Executive Officer, will preside over ... 1, the first day of Breast Cancer Awareness Month. ... campaign focused on the important benefits of Hologic,s 3D ... FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... 2014  Tasly Pharmaceuticals, Inc., the world,s leader ... today the launch of Deepure. Deepure ... men and women concerned with supporting their overall ... age while helping keep their health care cost ... herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and ...
(Date:9/30/2014)... 30, 2014 STUDY OBJECTIVES The ... to provide an overview of the current and ... drugs/therapeutics. The key objective is to present a ... as an important tool in the treatment of ... future strategies within the protein therapeutics market, which ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... 13 Dynatronics Corporation (Nasdaq: DYNT ) today announced ... , Net income for the fiscal first quarter was $68,625 ... ($.01 per share) for the comparable prior year period. Sales ... $7,996,149 for the first quarter of the prior fiscal year. ...
... Eli Lilly and Company (NYSE: LLY ) announced ... science and technology, and president, Lilly Research Laboratories, will ... also announced that Jan M. Lundberg, Ph.D., executive vice ... to become his successor. Paul is committed to working ...
Cached Medicine Technology:Dynatronics Announces Positive Financial Results for Quarter 2Dynatronics Announces Positive Financial Results for Quarter 3Dynatronics Announces Positive Financial Results for Quarter 4Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor 2Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor 3
(Date:10/1/2014)... (PRWEB) October 01, 2014 Phoseon Technology, ... , continues to expand the business worldwide. This rapid ... with additional capacity for manufacturing efforts. The company has ... last five years and expects this growth to continue ... curing technology gains worldwide adoption. , “We are ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
(Date:10/1/2014)... October is national Breast Cancer Awareness Month—an annual ... raising money for breast cancer research. Pelican Water is ... in the effort to find a cure. , ... having access to clean, healthy water. Research has shown ... forms of cancer. , The Problem of Chlorine ...
(Date:10/1/2014)... Washington, DC (PRWEB) October 01, 2014 ... of all retail generics increasing in price in the ... Information Services, Inc.’s (AIS) Drug Benefit News (DBN) interviewed ... this trend means for pharmacies and health plans. ... pace with rising generic acquisition costs, these cost increases ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 3
... the U.S. and Canada have been selected to participate ... initiative in immunotherapy funded by the National Cancer Institute ... will establish a network of top academic immunologists to ... patients, own immune systems to fight their cancer. , ...
... , WEDNESDAY, April 6 (HealthDay News) -- Poor ... have the condition diagnosed, but this disparity has decreased in ... data on children in California and found that the average ... born in 1992 to 3.8 years for those born in ...
... the April 5 White House Press Briefing, President Barack Obama ... in Congress from both political parties in order to avoid ... he has matched the initial House of Representatives, proposal to ... only in areas of priority. He expressed that neither side ...
... neonatal horse can be a challenging patient. Its immune system is ... like most infants it wants to stay close to mom. ... Pamela Wilkins , a professor of equine internal medicine and ... a new paper on equine neonatal intensive care. The ...
... to find such high levels of PCBs, highly toxic compounds ... a region such as the western coast of Africa", Ailette ... (UPV/EHU-Spain) and co-author of a study published in the journal ... which some studies have shown to be carcinogenic compounds, were ...
... over, newts and salamanders. The mouse may join you as ... Researchers are reporting that a simple chemical cocktail can coax ... in the first stages of a regenerating limb. Their study, ... the biological raw material for a new limb, appears in ...
Cached Medicine News:Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 2Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 3Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 4Health News:Autism Diagnoses Still More Likely in Richer Neighborhoods 2Health News:AADR applauds President Obama's support for maintaining biomedical research in FY11 2Health News:Treating newborn horses: A unique form of pediatrics 2Health News:Treating newborn horses: A unique form of pediatrics 3Health News:High levels of toxic compounds found on coasts of West Africa 2
... AFP IRMA,is an immunoradiometric assay ... (AFP) in serum. It is,intended ... in either of,two contexts:, (a) ... the,management of patients with,nonseminomatous testicular ...
Coat-A-Count PAP IRMA,is an immunoradiometric assay designed,for the quantitative measurement of,prostatic acid phosphatase (PAP) in,serum. It is intended strictly for in vitro,diagnostic u...
The MOSAIC PET scanner is designed to meet the exacting requirements of animal research imaging. Supported by proven Philips technology, MOSAIC provides a leading edge PET solution for reliable in-vi...
... EEG recording is assured even in the ... has high performance, high sensitivity amplifiers, high ... filter, shielded electrodes and a high performance ... is a complete and ready to ...
Medicine Products: